NCT02978183View on ClinicalTrials.gov

Evaluation of the Effectiveness of ST266 Ophthalmic Drops Compared to Placebo to Treat Allergic Conjunctivitis

PHASE2CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

December 31, 2016

Primary Completion Date

February 28, 2017

Study Completion Date

November 30, 2017

Conditions
Allergic Conjunctivitis
Interventions
BIOLOGICAL

ST266

One (1) drop of 1X ST266 ophthalmic eye drops will be administered to each eye 4 times a day for 8 days.

DRUG

Saline (0.9% NaCl)

One (1) drop of saline ophthalmic eye drops will be administered to each eye 4 times a day for 8 days.

Trial Locations (2)

38119

Memphis

01810

Andover

Sponsors
All Listed Sponsors
lead

Noveome Biotherapeutics, formerly Stemnion

INDUSTRY

NCT02978183 - Evaluation of the Effectiveness of ST266 Ophthalmic Drops Compared to Placebo to Treat Allergic Conjunctivitis | Biotech Hunter | Biotech Hunter